source
- Akeso and Summit report survival advantage for PD-1xVEGF combo over KeytrudaAt the American Society of Clinical Oncology (ASCO) 2026 meeting, Akeso Biopharma and its partner Summit Therapeutics announced new survival results for their experimental PD‑1×VEGF bispecific anti…
- GSK’s risvutatug rezetecan shows 18.5-month median overall survival in phase 3 SCLC trialGSK, together with Chinese partner Hansoh Pharma, reported results of its antibody‑drug conjugate risvutatug rezetecan (ris‑rez) in a phase 3 trial for relapsed small‑cell lung cancer. The study e…